Compare PII & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PII | LEGN |
|---|---|---|
| Founded | 1954 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.6B |
| IPO Year | 1994 | 2020 |
| Metric | PII | LEGN |
|---|---|---|
| Price | $52.35 | $18.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 12 |
| Target Price | ★ $62.27 | $61.33 |
| AVG Volume (30 Days) | 715.6K | ★ 1.8M |
| Earning Date | 04-27-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.05% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,152,000,000.00 | N/A |
| Revenue This Year | $1.20 | $42.68 |
| Revenue Next Year | $4.51 | $30.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $47.14 | $16.24 |
| 52 Week High | $77.98 | $37.50 |
| Indicator | PII | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 27.71 | 45.35 |
| Support Level | $52.22 | $17.81 |
| Resistance Level | $74.00 | $19.36 |
| Average True Range (ATR) | 1.94 | 0.80 |
| MACD | -0.14 | 0.15 |
| Stochastic Oscillator | 9.32 | 66.89 |
Polaris designs and manufactures off-road vehicles, including all-terrain vehicles and side-by-side vehicles for recreational, utility, military, and commercial purposes, snowmobiles, and on-road vehicles, along with the related replacement parts, garments, and accessories. The firm entered the marine market after acquiring Boat Holdings in 2018, offering exposure to pontoon and deck boat users. It is slated to divest its Indian motorcycle brand to Carolwood in the first quarter of 2026. Polaris products are retailed through more than 2,500 dealers in North America and 1,500 international dealers as well as more than 25 subsidiaries and 90 distributors in more than 100 countries outside North America.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.